[Galactosyltransferase isozyme II (GT-II) as a new tumor marker for ovarian cancers--especially for clear cell carcinoma].
Serum levels of galactosyltransferase (GT) and its isozyme (GT-II), which transfers galactose from UDP-galactose to N-acetylglucosamine etc., in gynecologic malignancies, were assayed. GT activity was assayed with UDP-[3H] galactose and ovalbumin as substrate, and GT-II was assayed by selectively removing GT-II from serum by immunoabsorption with immobilized monoclonal antibody 3872, followed by assay of bound GT activity. GT was not specific for cancer, but GT-II was positive in 74% of the ovarian cancer patients, and remarkably high serum levels were observed in mesonephroid cancers, indicating its possible usefulness as a new tumor marker. Immunohistochemical staining revealed that GT-II was localized on the cell surface and in the cytoplasm, suggesting its production by tumor cells.
Nozawa
S
S
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo.
Kiguchi
K
K
Yajima
M
M
Udagawa
Y
Y
Sakuma
T
T
Iizuka
R
R
Narisawa
S
S
Sakayori
M
M
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000201:enzymology; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood*; D005260:Female; D005700:Galactosyltransferases / Q000032:analysis / Q000097:blood* / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000032:analysis / Q000097:blood*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000201:enzymology; D011247:Pregnancy
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D007527:Isoenzymes; D005700:Galactosyltransferases